RCM Technologies, Inc. Announces Third Quarter 2026 Results

(NASDAQ:RCMT) RCM Technologies, Inc. announced financial results for the thirteen and thirty-nine weeks ended October 3, 2026. Revenue for the thirteen weeks ended October 3, 2026 was $73.4 million, up 4.4% from $70.3 million in the prior-year quarter. Gross profit for the current quarter was $19.9 million, a 2.7% increase from $19.4 million in the comparable prior quarter. GAAP net income for the current quarter was $2.7 million, or $0.37 per diluted share, compared to $2.3 million, or $0.30 per diluted share, in the prior-year quarter. Adjusted EBITDA (non-GAAP) for the current quarter was $6.3 million, up from $5.5 million in the comparable prior quarter, representing a 14.2% increase. Adjusted net income per diluted share (non-GAAP) for the current quarter was $0.53, compared to $0.42 in the prior-year quarter, an increase of 26.2%. For the thirty-nine weeks ended October 3, 2026, revenue was $250.3 million, a 7.4% increase from $232.9 million in the comparable prior-year period. Gross profit for the current period was $66.0 million, up 3.7% from $63.7 million in the prior-year period. GAAP net income for the current period was $11.5 million, or $1.56 per diluted share, compared to $10.2 million, or $1.34 per diluted share, in the prior-year period. Adjusted EBITDA (non-GAAP) for the current period was $23.8 million, up from $21.4 million in the prior-year period, an 11.0% increase. Adjusted net income per diluted share (non-GAAP) for the current period was $2.01, compared to $1.73 in the prior-year period, an increase of 16.2%. Segment revenue for the thirteen weeks ended October 3, 2026 was $33.7 million for Specialty Healthcare, $30.7 million for Engineering, and $8.9 million for Life Sciences, Data and Solutions. Gross profit margins for the current quarter were 25.5% for Specialty Healthcare, 25.9% for Engineering, and 37.7% for Life Sciences, Data and Solutions, with a consolidated margin of 27.1%. For the thirty-nine weeks ended October 3, 2026, segment revenue was $126.5 million for Specialty Healthcare, $96.4 million for Engineering, and $27.3 million for Life Sciences, Data and Solutions. Gross profit margins for the current period were 27.8% for Specialty Healthcare, 21.1% for Engineering, and 38.6% for Life Sciences, Data and Solutions, with a consolidated margin of 26.4%. As of October 3, 2026, cash was $1.9 million, accounts receivable and contract assets were $85.0 million, and total assets were $133.2 million. Total current liabilities as of October 3, 2026 were $47.9 million, and total liabilities were $80.2 million. Stockholders’ equity as of October 3, 2026 was $53.0 million. Net cash used in operating activities for the thirteen weeks ended October 3, 2026 was $3.7 million, and for the thirty-nine weeks ended October 3, 2026 was $6.3 million. The company used an estimated effective income tax rate of 27.0% for both periods presented.